An observational study in Carcinoma, Glioblastoma and Radiotherapy, sponsored by Swansea Bay University Health Board. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Swansea Bay University Health Board · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Carcinoma with a site in United Kingdom — 11 open to participants now, 20 under way, 11 of them phase 3. Carcinoma · United Kingdom.
Among the 67 studies in Carcinoma with a site in United Kingdom, this one is one of 2 that started in 2026, is one of 5 observational ones, reaches primary completion later than 15 of the 19 other live ones, and was the 66th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →11 of the 67 studies in Carcinoma with a site in United Kingdom are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United Kingdom, United States, Australia and 13 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18+
Auricula Biosciences Inc. · Sites in United Kingdom, United States, Canada
Ages 18+
Pfizer · Sites in United Kingdom, United States, Argentina and 28 more countries
Ages 18+
Cancer Research UK · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 20 · Phase 3 26 · Phase 4 2
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is close to the median of 165 across 129 observational studies indexed under Carcinoma.
Median enrollment 187 across the 62 interventional studies, 352 across the 5 observational. Of the 43 that completed or were terminated, 21 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 67 have an industry lead sponsor. The 10 most frequent:
Swansea Bay University Health Board is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
Swansea Bay University Health Board has 1 study filed under Carcinoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT02292641Imperial College LondonBeyond TME Origins | 2026-12 |
| NCT05873686Nuvectis Pharma, Inc.A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | 2027-03 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 67 studies in Carcinoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is:
This study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating:
The study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.
Background Advances in radiotherapy technology have allowed treatments to become more conformal with steeper dose gradients, meaning target volumes are smaller and dose to surrounding normal tissues reduced. This is possible, in part, due to improvements in imaging used in radiotherapy planning and in the development of Intensity Modulated Radiotherapy. The current standard of care for most tumour sites is for target volumes to be delineated on a planning CT scan, with additional information from diagnostic imaging such as MRI or PET which can be fused with the planning CT scan. MRI is known to give clearer images of soft tissues and tissue planes allowing for more accurate target volume delivery. The fusion of MRI to the planning CT scan to aid target volume delineation is a standard of care for certain tumour sites, e.g. brain, but not in others such as oesophagogastric cancers.
Optimisation of MRI protocols for Novel Tumour sites Our group undertook a scoping review into the use of MRI for radiotherapy target volume delineation for gastric cancers and has found that although there is evidence of improved contrast resolution with MRI in comparison to CT, clinical utility for radiotherapy planning is yet to be demonstrated. The research group has also performed a pilot study assessing the addition MRI to CT planning scans for radiotherapy planning for gastric cancers which demonstrated potential for clinical benefit. The limitations of this study were small patient numbers and that MRIs used were diagnostic scans optimised for liver imaging rather than gastric cancers. An issue identified was poor anatomical correlation of the MRI to CT planning scan due to differences in stomach filling. Our study will build on this work to optimise the MRI sequences for improved clarity of imaging and to identify and standardise optimal pre-examination preparation.
It is possible to acquire a range of MRI sequences with each giving different information. Furthermore, contrast agents may be used during image acquisition to improve visualisation of the target of interest. The choice of contrast agent and sequences depends on whether the aim is to assess the size/location of the tumour or to assess a functional aspect of the tumour allowing the potential to act as a predictive or prognostic imaging biomarker. This study aims to optimise the choice of MRI sequences for target volume delineation in various anatomical regions and to assess the potential impact of MR imaging on radiotherapy planning in anatomical regions where it is not currently routine practice. In the UK there is an ongoing similar study that aims to optimise the MRI sequences for use on MRI-Linear Accelerator (MR-Linac) machines. Our study will follow similar principles in order to optimise MRI sequences for radiotherapy planning from stand-alone MRI scanners. The investigators postulate that our findings will be more generalisable compared to the recruiting MR-Linac study, as the vast majority of UK Oncology Centres do not have access to MR-Linac machines.
The potential for an MRI-Adaptive workflow Radical (curative-intent) or neoadjuvant radiotherapy treatment is often delivered as multiple treatment fractions given over several weeks. The current standard of care is to generate a radiotherapy plan based on a pre-treatment CT planning scan with guidance from additional diagnostic investigations depending on tumour site. Unless an issue is detected during treatment, e.g. detected by the on-treatment cone-beam CT(CBCT) set-up verification process, the patient would complete their whole course of treatment as per the radiotherapy plan based on the pre-treatment CT planning scan. This does not account for changes in the position, size or shape of the tumour that occur over the whole radiotherapy treatment course. Clinicians therefore add margins around the target volume to account for these potential uncertainties, leading to a larger target volumes and increased dose to surrounding normal structures, which can lead to increased toxicity. A potential solution to this issue could be to re-image and re-plan during the treatment course, termed 'adaptive radiotherapy'. MRI is already utilised for adapted radiotherapy workflow, particularly when an MR-Linac is available. This study will explore whether a diagnostic MRI may be used for RT plan adaptation. Of note, similar strategies have been assessed using CBCT with a 'plan of the day' approach in bladder cancer and there is also ongoing work assessing the benefit of adapting RT based on a mid-treatment PET scan in the PEARL study for oropharyngeal cancers.
Exploring Imaging Biomarkers MRI can also be used to determine quantitative information about functional biological processes, via the use of quantitative imaging biomarkers. These are defined as 'an objective characteristic derived from an in vivo image measured on a ratio or interval scale as an indicator of normal biological processes, pathogenic processes, or a response to a therapeutic intervention'. Current protocols include sequences which can be used to estimate functional characteristics of a tumour and surrounding tissues which could act as a biomarker to predict response to treatment or likelihood of a patient developing toxicity from treatment. However, there is limited validation of these biomarkers in clinical settings, in particular there is a lack of data assessing the repeatability and reproducibility.
Rationale and Risks/Benefits MRI is a non-invasive imaging technique which does not rely on ionising radiation exposure. It gives clearer images of soft tissues and tissue planes allowing for more accurate target volume delineation. More accurate delineation may allow clinicians to use smaller margins and therefore to spare surrounding normal tissues from radiotherapy induced damage thereby reducing toxicity.
This is a non-interventional, prospective study and therefore the investigators do not anticipate any serious adverse events directly relating to the scanning protocols. Standard MRI safety screening will be conducted to minimise the risk of serious adverse events such as those caused by permitting non-MR Safe individuals (as outlined in the exclusion criteria) to approach the magnetic field (e.g., malfunction of cardiac pacemaker). This study will investigate contrast enhanced sequences using licensed IV gadolinium-based contrast agents. These are widely used in clinical practice and are generally well tolerated but can present a risk of severe allergic reaction in 0.004%-0.7% patients and if given to patients with impaired renal function there is a risk of nephrogenic systemic fibrosis. Such contrast agents will be given to patients in line with the university's contrast agent policy and always under the supervision of a clinician.
Pre-examination participant preparation may be achieved through administration of oral contrast/filling agents. These can be used to improve visibility of the stomach lining and provide organ distention where appropriate. Most commonly, water has been administered but other food grade, non-medicinal contrast agents have been explored, most notably fruit juices e.g., pineapple and blueberry, or milk based drinks. Prior to administration, all participants will undergo an allergy check. Selecting the optimal oral contrast agent for MRI to aid radiotherapy planning will depend on factors such as disease location, purpose for which MRI sequences are to be obtained and importantly patient preference. There is currently limited published data regarding which is the optimal choice of oral contrast agent with respect to the imaging quality and also the patient experience of taking oral contrast agents for MRI scans.
For patients participating in this study, their radiotherapy planning will be as standard of care and their inclusion in the study not have any effect on their radiotherapy pathway.
Hypotheses
Study Aims:
Optimisation of MRI protocols To have clinically-ready MRI protocols for use in clinical practice. This will entail optimising MRI sequences for radiotherapy planning, including optimising the pre-examination preparation and patient experience. Initial work will focus on 3 tumour sites
On completion of these subsites, proposed further anatomical sites include:
Secondary Aims:
Study Design The study will consist of three parallel strands. These strands form the underpinning methodology for individual sub-studies which will investigate different tumour sites.
Strand 1 - Optimising MRI protocols and assessing the effect of MRI-CT integration in the radiotherapy pathway
This strand will progress over 4 stages:
Optimisation of MRI protocols: Patient Volunteer Imaging Studies of Tumour/Normal Tissue Up to 20 patients per tumour site will be scanned alongside their standard treatment pathway to ascertain the best MRI sequences and parameters to obtain the highest quality images of the tumour and nearby organs of interest. Pre-examination tissue preparation (e.g. stomach filling volumes and material) for abdominal MRI will also examined and optimised. The goal would be to optimise images for improved expert rater acceptance and test feasibility of MRI for radiotherapy planning in patients. This stage will be considered complete once the success criteria is achieved.
Predefined success criteria for each organ/tumour site for - Strand 1 stage a Healthy Volunteer and stage b Patient Volunteer Studies:
- Two MRI physicists' opinions that sequences are adequately optimised to meet the requirements for radiotherapy planning.
Assessment of sequences may include review of specific sequence parameters (following international guidance on MRI in RT) and geometric distortion characterisation. The MRI Characteristics will be recorded and the Physicist Team Questionnaire will be completed.
Assessing the effect of MRI-CT integration in the radiotherapy pathway: Tumour definition/Target Volume Delineation To assess the effect of MRI-CT Integration in the radiotherapy pathway, acquired MRI scans with be used alongside the patient's CT planning scan to determine the benefits of MRI in tumour delineation. This section of the study will evaluate target volume delineation with and without MRI to determine the clinical benefit of having MR images available and fused to the planning CT scan at the time of RT target volume delineation by assessing the changes in dosimetry and target volumes when RT is planned with vs without MRI. Conformity indices will be calculated to determine the level of agreement between the paired plans. The effects of including MRI on the confidence rating of the clinician outlining the target volumes will also be evaluated as per the Outlining Clinician Questionnaire.
A minimum sample size of 10 patients with MRI scans will be acquired for these comparison studies.
Strand 2 - MRI-adapted radiotherapy Substudies will be developed in specific tumour sites to assess the utility of MRI during a course of radiotherapy (e.g. at the mid-point) to assess treatment response and allow for radiotherapy to be adapted for re-planning to focus on the residual tumour. The new plan will be compared to the original radiotherapy plan to determine the changes in target volume, dosimetry and dose to surrounding normal structures. Changes in predicted toxicity will be determined by using normal tissue complication models. If found to provide potential benefit in terms of predicted reduction in toxicity then this work would act as a pilot to guide the protocol of a future clinical trial to examine this further. A sample size of 10 patients will be acquired for these comparison studies.
Inclusion of patients in this study will be alongside their standard clinical pathway. Participating will not affect their standard radiotherapy pathway and the MRI obtained is purely for research purposes.
Strand 3 - Imaging biomarkers Sub-studies will evaluate MRI sequences that have the potential to act as functional biomarkers e.g. predicting response to treatment or likelihood of developing toxicity for selected tumour sites. For example, by using T2-weighted and DWI MRI sequences a measure of blood flow can be calculated and this is postulated to be predictive of response to radiotherapy.
Advanced sequences to be tested may include (but not confined to):
These images/spectra will then be analysed. Where feasible, the investigators will develop pilot studies that will compare to post-treatment outcomes, such as post-operative pathology, to assess the extent of tumour response to radiotherapy. This will allow identification of promising functional biomarkers which can then be studied in future research studies/clinical trials.
The participants for this study will be:
Inclusion Criteria for health volunteers:
Inclusion Criteria for patients:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Volunteers with no history of any medical issue which may affect the scan interpretation and who are eligible for MRI scanning
Other: MRI
Patients with the tumour of interest who are due to undergo radiotherapy and are eligible for MRI scanning
Other: MRI
This is an observational study with no interventions. Participants will undergo MRI scanning for research purposes and radiotherapy treatment will be delivered as per standard of care for the participants tumour type.
Optimisation of MRI images 1
Participant acceptability with average rating of 4 or higher on the Participant Questionnaire MRI Section Q1 and Q2
Time frame: From enrolment to analysis, on average 4-6 weeks
Optimisation of MRI images 2
Physics team expert opinion that the sequence is optimised, assessed as per the Physics Team Questionnaire by 2 independent expert medical physicists
Time frame: From enrolment to analysis, on average 4-6 weeks
Optimisation of MRI images 3
Visual grading characteristics analysis rating 4 or higher and deemed acceptable for clinical purposes by 3 independent clinicians as per the Image Properties Data Collection Form
Time frame: From enrolment to analysis, on average 4-6 weeks
Assess the effect of MRI-CT Integration in the radiotherapy pathway 1
This will involve analysis of radiotherapy plans produced with and without an MRI scan at the time of the CT planning scan, to include: Dosimetry Comparison (evaluation of differences in dose distributions delivered to target volumes and OARs);
Time frame: From enrolment to analysis, on average 4-6 weeks
Assess the effect of MRI-CT Integration in the radiotherapy pathway 2
This will involve analysis of radiotherapy plans produced with and without an MRI scan at the time of the CT planning scan, to include: Volumetric Comparison (assessment of differences in target and OAR delineation volumes);
Time frame: From enrolment to analysis, on average 4-6 weeks
Assess the effect of MRI-CT Integration in the radiotherapy pathway 3
This will involve analysis of radiotherapy plans produced with and without an MRI scan at the time of the CT planning scan, to include: Qualitative Confidence Assessment (expert ratings of confidence in contouring accuracy rated on a 5-point Likert scale as per Outlining Clinician Questionnaire)
Time frame: From enrolment to analysis, on average 4-6 weeks
Assess the effect of MRI-CT Integration in the radiotherapy pathway 4
This will involve analysis of radiotherapy plans produced with and without an MRI scan at the time of the CT planning scan, to include: Prediction of change in toxicity using normal tissue complication probability modelling
Time frame: From enrolment to analysis, on average 4-6 weeks
MRI-Adapted Radiotherapy 1
This will involve analysis of radiotherapy plans produced following an MRI scan during radiotherapy treatment and compared to the original radiotherapy plan, to include: Dosimetry Comparison (evaluation of differences in dose distributions delivered to target volumes and OARs);
Time frame: From enrolment to analysis, on average 4-6 weeks
MRI-Adapted Radiotherapy 2
This will involve analysis of radiotherapy plans produced following an MRI scan during radiotherapy treatment and compared to the original radiotherapy plan, to include: Volumetric Comparison (assessment of differences in target and OAR delineation volumes);
Time frame: From enrolment to analysis, on average 4-6 weeks
MRI-Adapted Radiotherapy 3
This will involve analysis of radiotherapy plans produced following an MRI scan during radiotherapy treatment and compared to the original radiotherapy plan, to include: Prediction of change in toxicity using normal tissue complication probability modelling
Time frame: From enrolment to analysis, on average 4-6 weeks
Quantitative Imaging Biomarkers
This exploratory end point will involve analysis of the feasibility, sensitivity and specificity of structural and functional MRI sequences identified as potential imaging biomarkers. This will include correlation of the potential imaging biomarker with patient outcomes including histological tumour regression grading for patients who go on to have surgery, disease progression on other radiological imaging (as per RECIST) and with CTCAE toxicity grading following radiotherapy treatment and with survival metrics e.g. progression free survival, cancer specific survival, overall survival.
Time frame: From enrolment until a maximum of 2 years after completing treatment
Plan to share: No
Start is estimated for May 2026; primary completion for Jan 2030, 44 months later.
Of 50 non-industry observational studies under Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29. This study's planned 44 months is below that.
Counting every sponsor, half of 62 studies reached it within 49 months; a quarter within 29 and three quarters within 166.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Swansea Bay University Health Board